gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SCLXHealthcareBiotechnology

Scilex Holding Company Common Stock (SCLX)

$1.70−7.10%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$1.61▼ 91.84% in range
Nov 4, 2025Low $1.61 · High $22.51Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Scilex Holding closed at $1.70 on Nov 5, down 7.10%, within 0.0% of its 52-week closing low. Volume of 79.9K shares was 1.85× its 20-day average (above normal).

Split-adjusted performance: -51.3% over one month, -78.9% over six months, -91.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $7.64M, down 22.8% from a year earlier, with a net margin of -1501.3%.

Short interest was 148.4K shares at the Oct 15 settlement, down 13.3% from the prior report (2.4% of float, 2.6 days to cover).

Market cap$12.0M7.0M shares
Revenue · quarter$7.6M−22.8% YoY
Diluted EPS$-16.65—
P/E · TTM—P/S 0.4×
Net margin-1,501.3%Gross 51.9%
Dividend yieldNone
52-week range1.70 – 22.51−92.4% from high
Volume79.9K1.85× 20-day avg
Volatility · 60d70.2%Annualised
Short % of float2.4%2.6 days to cover
Net cash-$82.5MCash $581.0K
Next earnings—Not scheduled
Split-adjusted performance
1W −17.5%1M −51.3%3M −75.5%6M −78.9%YTD −86.1%1Y −91.4%3Y −97.4%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum6
Revenue growth32
Net margin25
Value (low P/E)—
Size9

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short148.4K−13.3% vs prior
Days to cover2.6Settled Oct 15
% of float2.4%
Short vol. 10d48.0%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SCLXScilex Holding$1.70−7.10%−78.9%−22.8%−1501.3%—$12.0M
TCRXTScan Therapeutics$0.1818−13.43%−85.0%−65.8%−2888.6%—$12.3MCompare
PASGPassage Bio$3.46−1.42%−15.2%———$11.1MCompare
BCDABioCardia$0.8900−2.53%−18.3%———$13.5MCompare
DYAIDyadic International$0.3401−7.25%−54.3%−0.6%−221.0%—$13.6MCompare
INTSIntensity Therapeutics$3.10−11.43%−39.3%———$10.1MCompare
ATYRaTyr Pharma$6.03−2.43%−83.6%———$15.1MCompare
ABOSAcumen Pharmaceuticals$0.2138−1.16%−91.3%———$15.5MCompare
JSPRJasper Therapeutics$0.4692−8.20%−48.3%———$15.6MCompare

News about Scilex Holding

All news →
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPGlobeNewswire Inc. · Jul 6, 2026▲ PositiveScilex (SCLX) Stock Jumps After Dream Bowl Meme Coin Listing Update: Why Is It Moving?Benzinga · Jun 17, 2026▲ PositiveScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesBenzinga · Jun 4, 2026▲ PositiveScilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026Benzinga · May 22, 2026NeutralScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings LimitedBenzinga · May 5, 2026▲ Positive

Quick answers

What does Scilex Holding do?
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.
What is SCLX's market cap?
$11.96M, based on the Nov 5 close of $1.70.
Does Scilex Holding pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SCLX is sold short?
148.4K shares, 2.4% of float, as of Oct 15, 2026.
What sector is SCLX in?
Healthcare, in the Biotechnology industry.

About Scilex Holding

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

HQ: Palo Alto, CA34 employeesListed Nov 11, 2022scilexholding.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology